Introduction: Morbidity and mortality associated with invasive fungal infections (IFIs) remains unacceptably high. Such diseases represent a substantial burden to the healthcare system. New options are needed to address antifungal resistance in existing and emerging pathogens and improve treatment outcomes while minimizing drug-related toxicities and interactions. Awareness of new and potential future options is of great value for those healthcare professionals who care for patients with IFIs. Areas covered: A search of PubMed, infectious diseases conference abstracts and reference lists from relevant publications was conducted and relevant information abstracted. This review describes the limitations of existing systemic antifungal therapies (e.g., resistance, drug-drug interactions, drug-related toxicities) and summarizes data regarding several emerging antifungal compounds including (but not limited to) new triazoles (e.g. isavuconazole, ravuconazole), echinocandins (e.g., aminocandin) and nikkomycin Z. Agents in clinical trials such as (but not limited to) new triazoles (e.g., isavuconazole, ravuconazole), echinocandins (e.g., aminocandin) and nikkomycin are included. New formulations of existing drugs including reformulations of miconazole, posaconazole and amphotericin B are also reviewed. Finally, new or novel administration strategies for existing drugs such as combination antifungal therapy, antifungal dose escalation, adjunctive use of iron chelators and preemptive therapy are discussed. Expert opinion: All present antifungal agents have some deficiencies in antifungal spectra, toxicity, pharmacokinetics and/or drug-drug interactions, making them less than ideal for some fungal infections. Therefore, there remains an urgent need to find safe, effective, rapidly fungicidal, broad-spectrum antifungal agents with excellent pharmacodynamics to effectively eliminate the fungus from the body with short antifungal courses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14728214.2011.607811 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Narrative Review of Fungal Periprosthetic Joint Infections of the Hip and Knee: Risk Factors, Microbiological Profiles, and Treatment Challenges.
J Clin Med
January 2025
Department of Internal Medicine, 4th Military Clinical Hospital, 50-981 Wroclaw, Poland.
Fungal periprosthetic joint infections (PJIs) are rare but increasingly recognized complications following total joint arthroplasty (TJA). While remains the most common pathogen, non-albicans species and other fungi, such as , have gained prominence. These infections often present with subtle clinical features and affect patients with significant comorbidities or immunosuppression.
View Article and Find Full Text PDFInsight into the Structure of Antifungal Cyrmenins: Conformational Studies of Unique Dehydroamino Acid, O-Methyldehydroserine.
Int J Mol Sci
January 2025
Faculty of Chemistry and Pharmacy, University of Opole, Oleska 48, 45-052 Opole, Poland.
O-Methyldehydroserine, ΔSer(Me), is a non-standard α,β-dehydroamino acid, which occurs naturally in Cyrmenins with potential pharmaceutical application. The C-terminal part and the side chain of the ΔSer(Me) residue constitute the β-methoxyacrylate unit, responsible for antifungal activity of Cyrmenins. The short model, Ac-ΔSer(Me)-OMe, was analyzed considering the geometrical isomer Z () and E ().
View Article and Find Full Text PDFA B-Box (BBX) Transcription Factor from Cucumber, CsCOL9 Positively Regulates Resistance of Host Plant to .
Int J Mol Sci
January 2025
College of Plant Protection, Henan Agricultural University, Zhengzhou 450046, China.
B-box (BBX) transcription factors play crucial roles in plant growth, development, and defense responses to biotic and abiotic stresses. In this study, we cloned a BBX transcription factor gene, from cucumber and analyzed its role in the plant's defense against the feeding of . is expressed throughout all developmental stages in cucumber, with the highest expression in the leaves.
View Article and Find Full Text PDFRepurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.
Int J Mol Sci
January 2025
Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.
Eumycetoma, a chronic fungal infection caused by , is a neglected tropical disease characterized by tumor-like growths that can lead to permanent disability and deformities if untreated. Predominantly affecting regions in Africa, South America, and Asia, it imposes significant physical, social, and economic burdens. Current treatments, including antifungal drugs like itraconazole, often show variable efficacy, with severe cases necessitating surgical intervention or amputation.
View Article and Find Full Text PDFThe Synergy of Chitosan and Azoxystrobin Against Is Modulated by Selected ABC Transporters.
Int J Mol Sci
December 2024
Plant Breeding and Acclimatization Institute-National Research Institute, Radzikow, 05-870 Blonie, Poland.
Article Synopsis
- Innovative strategies are needed to combat fungal pathogens for sustainable crop protection, with traditional fungicides facing resistance issues due to their single-target action.
- The study investigated the synergistic effects of chitosan (CS) and the fungicide azoxystrobin, finding a high synergy score that significantly improves antifungal efficacy.
- Additionally, combining CS and azoxystrobin with RNA interference techniques enhanced fungal control, highlighting a promising eco-friendly approach and the need for further research on its molecular mechanisms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!